SAGIMET BIOSCIENCES INC-A (SGMT) Stock News
NASDAQ:SGMT - Nasdaq - US7867001049 - Common Stock - Currency: USD
SGMT Latest News, Press Relases and Analysis
Here are the top movers in Thursday's session.
Keep an eye on the top gainers and losers in Thursday's session, as they reflect the most notable price movements.
These stocks are moving in today's pre-market session
As we await the opening of the US market on Wednesday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
5 Ways Trump’s ‘Big, Beautiful Bill’ Could Impact Your Wallet
While the bill promises growth and relief in some areas, it also introduces cuts and changes that could impact everything from healthcare premiums to loans.
Mentions: STRF
Sagimet Biosciences to Host Virtual KOL Event, “A New Mechanism of Action in Treating Acne: Update on Positive Phase 3 Denifanstat Trial for the Treatment of Moderate to Severe Acne” on June 16, 2025
SAN MATEO, Calif., June 09, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel...
Sagimet's Partner Achieves Positive Results With Oral Acne Drug In Phase 3 Trial In China, Stock Jumps
Denifanstat showed positive Phase 3 results in acne, meeting all goals with strong safety, as Sagimet pushes ahead with a second FASN inhibitor trial.
Mentions: GSK
Sagimet Biosciences Announces Positive Phase 3 Results for Denifanstat for the Treatment of Moderate-to-Severe Acne from Partner Ascletis
Sagimet Biosciences Announces Positive Phase 3 Results for Denifanstat for the Treatment of Moderate-to-Severe Acne from Partner Ascletis
Denifanstat met all primary and secondary endpoints versus placebo Denifanstat was well tolerated Oral FASN inhibitors offer a novel mechanism of action...
Ascletis Announces Phase III Trial of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne, Meets All Endpoints
Denifanstat (ASC40), a once-daily oral fatty acid synthase (FASN) inhibitor, demonstrated statistically significant and clinically meaningful improvement...
Sagimet Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Updates
Phase 1 clinical trial to evaluate the pharmacokinetics (PK) of a combination of denifanstat and resmetirom expected to initiate in 2H 2025; data readout expected 1H 2026
Sagimet Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Updates
Phase 1 clinical trial to evaluate the pharmacokinetics (PK) of a combination of denifanstat and resmetirom expected to initiate in 2H 2025; data readout...
Sagimet Biosciences Announces Upcoming Presentations at EASL Congress 2025
Sagimet Biosciences Announces Upcoming Presentations at EASL Congress 2025
SAN MATEO, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company...
Sagimet Biosciences Reports Full Year 2024 Financial Results and Provides Corporate Updates
Sagimet Biosciences Reports Full Year 2024 Financial Results and Provides Corporate Updates
Denifanstat Phase 3 MASH program initiated in Q4 2024; patient screening expected to start in 1H 2025 Denifanstat received Breakthrough Therapy...
Sagimet Biosciences Announces Clearance of IND for FASN Inhibitor TVB-3567, to be Developed for the Treatment of Acne
Sagimet Biosciences Announces Clearance of IND for FASN Inhibitor TVB-3567, to be Developed for the Treatment of Acne
TVB-3567 is the Company’s second fatty acid synthase (FASN) inhibitor First-in-human Phase 1 trial initiation planned in 2025 SAN MATEO, Calif., March ...
Sagimet Biosciences Announces Oral Presentation at the MASH Pathogenesis and Therapeutic Approaches Keystone Symposium
Sagimet Biosciences Announces Oral Presentation at the 9th Annual MASH-TAG 2025 Conference
Sagimet Biosciences to Participate in the Piper Sandler 36th Annual Healthcare Conference
Sagimet Biosciences to Participate in the Piper Sandler 36th Annual Healthcare Conference
SAN MATEO, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company...
Sagimet Biosciences Presents Clinical Denifanstat and Preclinical FASN Inhibitor Data at AASLD - The Liver Meeting® 2024
Sagimet Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
Sagimet Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
Denifanstat received Breakthrough Therapy designation from FDA for MASH Results from Phase 2b FASCINATE-2 study of denifanstat published in The Lancet...
Ascletis Completes Enrollment of Phase III Trial of ASC40 (Denifanstat) Once-Daily Oral Tablet for Treatment of Acne
/PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces completion of enrollment of 480 patients for Phase III clinical trial of ASC40...
Sagimet Biosciences to Participate in the UBS Global Healthcare Conference
Sagimet Biosciences to Participate in the UBS Global Healthcare Conference
SAN MATEO, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company...
Madrigal Catapults After Novo's Wegovy Proves It's No 'Silver Bullet' In MASH
Madrigal sells an approved MASH treatment that blasted third-quarter sales views out of the water.
Sagimet Biosciences Announces Successful Completion of End-of-Phase 2 Interactions with FDA on the Development of Denifanstat for MASH; Phase 3 Program Initiation Expected by End of 2024
The planned registration program consists of two double-blind, placebo-controlled multicenter Phase 3 trials, FASCINATE-3 and FASCINIT, to evaluate the...
Sagimet Biosciences Announces Upcoming Presentations at AASLD - The Liver Meeting® 2024
SAN MATEO, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company...